HK1070063A1 - Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments - Google Patents
Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments Download PDFInfo
- Publication number
- HK1070063A1 HK1070063A1 HK05102726A HK05102726A HK1070063A1 HK 1070063 A1 HK1070063 A1 HK 1070063A1 HK 05102726 A HK05102726 A HK 05102726A HK 05102726 A HK05102726 A HK 05102726A HK 1070063 A1 HK1070063 A1 HK 1070063A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- group
- polymorph
- water
- lithium
- potassium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01118593.1 | 2001-08-02 | ||
EP01118593 | 2001-08-02 | ||
EP01130180 | 2001-12-19 | ||
EP01130180.1 | 2001-12-19 | ||
PCT/EP2002/008466 WO2003014079A1 (en) | 2001-08-02 | 2002-07-30 | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
HK1070063A1 true HK1070063A1 (en) | 2005-06-10 |
HK1070063B HK1070063B (en) | 2007-03-09 |
Family
ID=
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100899297B1 (ko) | 플리반세린의 안정한 다형체, 이의 기술적 제조 방법 및 이를 포함하는 약제학적 조성물 | |
US7420057B2 (en) | Stable polymorph of flibanserin | |
EP1319003B1 (en) | Xanthine phosphodiesterase v inhibitors | |
FI79841C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla aminotetralinderivat. | |
AU2002331361A1 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
JP3090305B2 (ja) | 2−(2−アミノ−1,6−ジヒドロ−6−オキソ−プリン−9−イル)メトキシ−1,3−プロパンジオール誘導体 | |
AU2001291022A1 (en) | Xanthine phosphodiesterase v inhibitors | |
EP0179855B1 (en) | Dopamine agonists | |
JPH0825997B2 (ja) | 3−アミノプロピルオキシフェニル誘導体、その製法およびそれらを含有する医薬組成物 | |
HK1070063B (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
US4616011A (en) | Novel indole derivatives and pharmaceutical compositions containing same | |
HK1040399A1 (zh) | N-取代的氮雜二環庚烷衍生物及其製備方法和用途 | |
ZA200309586B (en) | Stable polymorph of flibanserin technical process for its preparation and the use thereof for preparing medicaments | |
NO326098B1 (no) | Stabil polymorf av flibanserin, teknisk fremgangsmate for fremstilling derav og anvendelse derav for fremstlling av medikamenter | |
BR122012029907B1 (pt) | A crystal polymorphine (form a) of flibanserin 1, its use, process for the preparation of flibanserin 1, and pharmaceutical compositions | |
IE46273B1 (en) | 1-(naphthylethyl)imidazole derivatives | |
JPH0570467A (ja) | アミノ酸置換チアゼトキノリン−3−カルボン酸誘導体 | |
HK1056550B (en) | Xanthine phosphodiesterase v inhibitors | |
EP1790652A1 (en) | Polycyclic guanine phosphodiesterase V inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: ADDITION OF INVENTOR: SCHNEIDER, HEINRICH Effective date: 20061025 |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150730 |